2022 ICD-10-CM Code C34.32

Malignant neoplasm of lower lobe, left bronchus or lung

Version 2021

Valid for Submission

ICD-10:C34.32
Short Description:Malignant neoplasm of lower lobe, left bronchus or lung
Long Description:Malignant neoplasm of lower lobe, left bronchus or lung

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of respiratory and intrathoracic organs (C30-C39)
      • Malignant neoplasm of bronchus and lung (C34)

C34.32 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of lower lobe, left bronchus or lung. The code C34.32 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.

The ICD-10-CM code C34.32 might also be used to specify conditions or terms like adenocarcinoma of left lung, malignant epithelial neoplasm of bronchus, malignant neoplasm of lower lobe bronchus, malignant neoplasm of lower lobe of left lung, neoplasm of bronchus of left lower lobe , primary adenocarcinoma of lower lobe of left lung, etc.

The code C34.32 is linked to some Quality Measures as part of Medicare's Quality Payment Program (QPP). When this code is used as part of a patient's medical record the following Quality Measures might apply: Lung Cancer Reporting (biopsy/cytology Specimens) , Lung Cancer Reporting (resection Specimens).

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

Convert C34.32 to ICD-9 Code

The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C34.32 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.

Quality Payment Program Measures

When code C34.32 is part of the patient's diagnoses the following Quality Measures apply and affect reimbursement. The objective of Medicare's Quality Measures is to improve patient care by making it more: effective, safe, efficient, patient-centered and equitable.

Quality Measure Description Quality Domain Measure Type High Priority Submission Methods
Lung Cancer Reporting (Biopsy/Cytology Specimens)Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS) with an explanation included in the pathology report.Communication and Care CoordinationProcessYESClaims, Registry
Lung Cancer Reporting (Resection Specimens)Pathology reports based on resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type.Communication and Care CoordinationProcessYESClaims, Registry

Information for Patients


Lung Cancer

What is lung cancer?

Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.

There are two main types: small cell lung cancer and non-small cell lung cancer. These two types grow differently and are treated differently. Non-small cell lung cancer is the more common type.

Who is at risk for lung cancer?

Lung cancer can affect anyone, but there are certain factors that raise your risk of getting it:

What are the symptoms of lung cancer?

Sometimes lung cancer does not cause any signs or symptoms. It may be found during a chest x-ray done for another condition.

If you do have symptoms, they may include

How is lung cancer diagnosed?

Your health care provider may use many tools to make a diagnosis:

If you do have lung cancer, your provider will do other tests to find out how far it has spread through the lungs, lymph nodes, and the rest of the body. This is called staging. Knowing the type and stage of lung cancer you have helps your provider decide what kind of treatment you need.

What are the treatments for lung cancer?

For most patients with lung cancer, current treatments do not cure the cancer.

Your treatment will depend on which type of lung cancer you have, how far it has spread, your overall health, and other factors. You may get more than one type of treatment.

The treatments for small cell lung cancer include

The treatments for non-small cell lung cancer include

Can lung cancer be prevented?

Avoiding the risk factors may help to prevent lung cancer:

NIH: National Cancer Institute


[Learn More in MedlinePlus]

Lung cancer

Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent.

Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years.

Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.


[Learn More in MedlinePlus]

Non-Small Cell Lung Cancer Summary Learn about non-small cell lung cancer risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]

Code History

  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)